Return to search results.
Complete title: A Phase 2, Randomized Study to Assess the Safety and Anti-Cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections that are Resistant or Refractory to Treatment with Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipient
|Research Study Number||2601.00|
|Principal Investigator||Michael Boeckh, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Solid Tumors; Cytomegalovirus (CMV)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.